Achilles Therapeutics appoints Lee M. Stern as VP, IR & External Communications

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours today announced the appointment of Lee M. Stern as VP, IR & External Communications where he will lead investor and financial communications activities.

Lee joins Achilles with over 20 years of experience in investor relations, corporate finance, and corporate communications within the biotechnology sector. “We are delighted to welcome Lee to our growing team in this new, US-based role,” said Dr. Iraj Ali, CEO of Achilles. “Lee’s experience in the healthcare industry, strong relationships with the financial community, and understanding of the capital markets will all be assets for Achilles as we progress towards obtaining initial data from our two Phase I/IIa clinical trials – CHIRON in non-small cell lung cancer and THETIS in melanoma – expected in 2021.”

Lee joins Achilles from Solebury Trout where he was a Managing Director in its Life Sciences practice. Lee received an MBA from The Wharton School of the University of Pennsylvania and a BS in Quantitative Economics from Tufts University. He is also a CFA® charterholder.

Back to News and insights